These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 3692120)
1. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia]. Efendieva EG; Dashkova NG Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120 [No Abstract] [Full Text] [Related]
2. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence. Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366 [TBL] [Abstract][Full Text] [Related]
3. The effectiveness of deferiprone in thalassemia. Dogherty P; Einarson T; Koren G; Sher G Blood; 1997 Jul; 90(2):894. PubMed ID: 9226195 [No Abstract] [Full Text] [Related]
4. Medical management of beta-thalassemia. Lerner N Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747 [No Abstract] [Full Text] [Related]
5. [Thalassemia major: chelating therapy with deferoxamine]. Abreu de Miani MS; Sanchis de Herrlein MS; PeƱalver JA Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934 [No Abstract] [Full Text] [Related]
6. Iron chelators for thalassaemia. Hershko C; Konijn AM; Link G Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877 [No Abstract] [Full Text] [Related]
8. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously]. Ferrara M; Galdo Capotorti M; Ponte G; Esposito L Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400 [No Abstract] [Full Text] [Related]
13. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620 [TBL] [Abstract][Full Text] [Related]
14. Recognition and treatment of iron overload. Brown EB Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439 [No Abstract] [Full Text] [Related]
15. Treatment of iron overload in Cooley's anemia. Cohen A; Mizanin J; Schwartz E Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130 [No Abstract] [Full Text] [Related]
16. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337 [TBL] [Abstract][Full Text] [Related]
17. Deferiprone. Piga A; Roggero S; Salussolia I; Massano D; Serra M; Longo F Ann N Y Acad Sci; 2010 Aug; 1202():75-8. PubMed ID: 20712776 [TBL] [Abstract][Full Text] [Related]
18. Hepatic iron stores in thalassemia: non-invasive magnetic measurements. Brittenham GM; Allen CJ; Farrell DE; Harris JW Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744 [No Abstract] [Full Text] [Related]
19. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Hershko C; Rachmilewitz EA Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354 [No Abstract] [Full Text] [Related]
20. Iron mobilization using chelation and phlebotomy. Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]